Viral hepatitis has long struggled to attract public policy attention – especially in comparison to HIV. Currently, however, important advances appear to be taking place at different levels (global, regional,and national).
The 69th World Health Assembly (May 2016) adopted the global health sector strategy on viral hepatitis. The latter introduces, for the first time, global targets for viral hepatitis (i.e. a 10% reduction in mortality by 2020 and a 30% reduction in new cases of hepatitis B and C).
In September 2016, the WHO action plan on viral hepatitis for the European region 2016-2021 will be presented for endorsement at the 66th session of the WHO Regional Committee for Europe. Finally, an increasing number of Member States are developing national plans on viral hepatitis (e.g. Spain, Portugal, Turkey, Albania, Georgia, etc.).
A nuclear receptor links HIV drugs with liver disease
Physical activity linked to reduced risk of liver cancer
MICROB-PREDICT – €15 million EU funded microbiome research project kicks off